| Patient | Voltaire |
|---|---|
| Date of birth | 1942-11-21 |
| Identifiers | MRN HR-EN002-SYN; SSN (made up) 000-02-5174 |
| Document date | 2026-05-06 |
| Author | Honorine Delacroix-Mensah, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review during weekly radiotherapy. [S]
Voltaire returns two weeks after starting the pain plan. He had the first radiotherapy fraction a week ago and the second this morning. Since the first fraction he has passed urine more often, about every two hours by day and twice at night, with mild burning, but the stream is steady and there have been no clots; the urine is pale pink on some days. He takes acetaminophen three times a day and has used eight half tablets of oxycodone in fourteen days, mostly in the evening, with good relief and no drowsiness, confusion, or falls; seven tablets remain in the locked box, and he has taken nothing else for pain or sleep. His bowels open daily on polyethylene glycol and senna. The palliative care team visited him at home last week. The physical therapist from the wellness visit has not yet come. He has lost 0.5 kg and drinks the supplement once a day. He wrote every morning this week. [S]
| Element | Detail |
|---|---|
| Radiotherapy | Fractions 1 and 2 of 6 given; mild frequency and burning |
| Voiding | Steady stream; nocturia twice; residual 120 mL |
| Pain | 2 of 10 on acetaminophen and about one half tablet of oxycodone a day |
| Opioid safety | Eight half tablets used in fourteen days; no sedation, falls, or other sedatives |
| Weight | 53.0 kg, down 0.5 kg |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | More tired on treatment days; weight down 0.5 kg |
| Genitourinary | Positive | Frequency every two hours, nocturia twice, mild burning; pale pink urine on some days; no clots |
| Gastrointestinal | Negative | Bowels open daily; no diarrhea or rectal bleeding |
| Neurological | Negative | No drowsiness, confusion, or falls |
| Psychiatric | Negative | Mood steady; sleeping about five hours |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Diphenhydramine 25 mg oral capsule, one capsule at night for sleep (over the counter) | One capsule at bedtime | Oral route | 2025-09-01 to 2026-04-06 | stopped | S |
| Tamsulosin 0.4 mg oral capsule, one capsule at bedtime | One capsule 30 minutes after the evening meal | Oral route | 2026-04-06 | active | S |
| Polyethylene glycol 3350, 17 g in a glass of water once daily | 17 g dissolved in water once daily | Oral route | 2024-01-15 | active | S |
| Cefpodoxime 200 mg oral tablet, one tablet by mouth twice daily for 7 days | One tablet twice daily with food for 7 days | Oral route | 2026-04-20 to 2026-04-26 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth three times daily (3 g a day) | Two tablets three times daily; no more than 3 g a day | Oral route | 2026-04-22 | active | S |
| Oxycodone 5 mg oral tablet, one half tablet (2.5 mg) by mouth every 6 hours if needed for bladder pain not relieved by acetaminophen, no more than three doses a day; 15 tablets dispensed | Half a tablet every 6 hours as needed; no more than three half tablets a day | Oral route | 2026-04-22 | active | S |
| Sennosides 8.6 mg oral tablet, two tablets at bedtime while taking oxycodone | Two tablets at bedtime | Oral route | 2026-04-22 | active | S |
| Naloxone 4 mg nasal spray, one spray in one nostril for suspected opioid overdose; call 911; may repeat in 2 to 3 minutes in the other nostril | One spray for suspected overdose; repeat after 2 to 3 minutes if no response | Nasal route | 2026-04-22 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-06 | Body height | 170 | cm | S |
| 2026-05-06 | Body weight | 53 | kg | S |
| 2026-05-06 | Body mass index (BMI) [Ratio] | 18.3 | kg/m2 | S |
| 2026-05-06 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-05-06 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-05-06 | Heart rate | 80 | /min | S |
| 2026-05-06 | Respiratory rate | 16 | /min | S |
| 2026-05-06 | Body temperature | 36.7 | Cel | S |
| 2026-05-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-06 | Hemoglobin [Mass/volume] in Blood | 10.8 | g/dL | 13.2-16.6 g/dL | Low | S |
| 2026-05-06 | Leukocytes [#/volume] in Blood by Automated count | 6.9 | 10*3/uL | 3.4-9.6 10*3/uL | Normal | S |
| 2026-05-06 | Platelets [#/volume] in Blood by Automated count | 231 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-05-06 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-06 | Creatinine [Mass/volume] in Serum or Plasma | 1.2 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-05-06 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 60 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-06 | US Urinary bladder Volume post void | 120 | mL | Below 100 mL; 300 mL or more suggests chronic retention | High | S |
| 2026-05-06 | International Prostate Symptom Score [IPSS] | 15 | {score} | S | ||
| 2026-05-06 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | {score} | S |
Vital signs recorded on 2026-05-06; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin, alert, and lively; not drowsy; pupils normal size |
| Cardiovascular | Blood pressure 122/68 mmHg; heart rate 80, regular |
| Respiratory | Respiratory rate 16; oxygen saturation 96 percent |
| Abdomen | Soft; mild suprapubic tenderness; bladder not palpable |
| Skin | No skin reaction over the pelvis |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Visible blood in the urine for three weeks with clots, and a weak stream, straining, and frequent small voids, in a man of 83; under evaluation | resolved | confirmed | R31.0 | S — Synthetic presenting problem echoing his documented urinary complaints and last illness; superseded by the diagnosis at the third chronic-care visit. |
| Chronic urinary retention with overflow (post-void residual 460 mL at intake), worsened by a nightly anticholinergic sleep aid; drained by an indwelling catheter | active | confirmed | R33.8 | S — Synthetic finding echoing the strangury and catheterization documented in his last weeks. |
| Acute kidney injury from bladder outlet obstruction (creatinine 1.68 mg/dL, from 1.1 mg/dL a year earlier) | resolved | confirmed | N17.9 | S — Synthetic finding; it echoes, without asserting, the later encyclopedia term uremia. |
| Benign prostatic hyperplasia with lower urinary tract symptoms: prostate about 78 mL on CT, enlarged, firm, and smooth on examination, PSA 6.4 ng/mL with a PSA density of 0.08; no prostate biopsy, by shared decision | active | confirmed | N40.1 | S — Synthetic diagnosis echoing the very large prostate described at the 1778 autopsy; whether that prostate was malignant is unknown (CLM-0012). |
| Squamous cell carcinoma of the bladder, keratinizing, posterior wall extending to the dome, muscle-invasive with extravesical extension (clinical stage cT3b N0 M0, stage IIIA), pure squamous histology without a urothelial component; treated with palliative-intent hypofractionated radiotherapy by shared decision | active | confirmed | C67.4 | S — Synthetic modern diagnosis confirmed by resection pathology. His bladder disease at autopsy is documented (D); calling it squamous cell carcinoma is a 2025 retrospective interpretation (R, disputed). |
| Chronic constipation, lifelong by his account, with long use of laxatives and self-given enemas | active | confirmed | K59.09 | S — Synthetic modern problem echoing his documented colic, purges, and enemas; no diagnosis of inflammatory bowel disease is made. |
| Febrile catheter-associated urinary tract infection with Escherichia coli, five days after bladder tumor resection; treated with cefpodoxime and a catheter change; resolved | resolved | confirmed | T83.511A | S — Synthetic intercurrent infection; it echoes, without asserting, the infected urine described in his last weeks (CLM-0009). |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count and kidney function during radiotherapy | At each visit during treatment | Completed today | Hemoglobin 10.8 g/dL, white count 6.9, platelets 231; creatinine 1.20 mg/dL (eGFR 60), potassium 4.4 mmol/L; stable |
| Examination | Post-void residual | At baseline when retention is suspected, after a trial without catheter, and when symptoms change | Completed today | 120 mL, stable |
| Survey | IPSS | Baseline and at every follow-up visit (CMID BPH) | Completed today | 15, moderate; frequency from radiotherapy |
| Survey | Pain intensity (0 to 10) | At every visit with cancer pain | Completed today | 2 of 10 |
| Examination | Radiation toxicity (bladder and bowel) | Weekly during radiotherapy | Completed today | Grade 1 cystitis; no bowel toxicity or skin reaction |
| Medication safety | Opioid follow-up: benefit, sedation, falls, constipation, use against the plan, prescription monitoring program, and naloxone at home | Within 1 to 4 weeks of starting, then at least every three months | Completed today | Eight half tablets in fourteen days, as prescribed; no sedation or falls; bowels regular; prescription monitoring program shows only this prescription; naloxone at home and his assistant trained |
| Referral | Home physical therapy for strength and balance | Within one to two weeks of the falls assessment | Deferred | Missed: home physical therapy ordered at the wellness visit has not started because the agency had no therapist free. No harm: he has had no falls. Corrective action: the clinic arranged a second agency, which will visit this week, and gave him a printed set of chair exercises in the meantime |
| Self-management | Weight and nutrition | At every visit while weight is falling | Completed today | 53.0 kg, down 0.5 kg; supplement once a day; asked to take it twice |
| Imaging | Bladder cancer surveillance schedule (cystoscopy and cytology for NMIBC; CT every 6 to 12 months after cystectomy) | Applies after NMIBC treatment or cystectomy | Not indicated | Neither applies: he has muscle-invasive disease treated with palliative-intent radiotherapy, so response is judged by symptoms, with cystoscopy or CT only if they would change care |
Goal progress:
Guideline basis: Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024) (2024); NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 3.2026 (including non-urothelial histologies) (2026); EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer (2026); Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment (Hafeez S, et al.) (2017); Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 (2023); CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022); American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023); Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology (2018); CMID: Clinical Monitoring Intelligence Database, urologic cancer and benign prostatic hyperplasia monographs (2026); Falls Prevention in Community-Dwelling Older Adults: Interventions (2024)
Follow-up: Chronic-care review in two weeks, after the fourth fraction; call for clots, a weak stream or inability to pass urine, fever, or pain not controlled. [S]